Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study
David Lau, Eleftheria Kalaitzaki, David N Church, Hardev Pandha, Ian Tomlinson, Nicola Annels, Marco Gerlinger, Francesco Sclafani, Gillian Smith, Ruwaida Begum, Richard Crux, Angela Gillbanks, Sarah Wordsworth, Ian Chau, Naureen Starling, David Cunningham, Tony Dhillon
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study'. Together they form a unique fingerprint.